Quetiapine is suitable for adults. Quetiapine is not licensed for use in children under 18 years of age. However, it may sometimes be prescribed by specialists to treat schizophrenia or mania in ...

Quetiapine is a generic drug prescribed to treat the symptoms of schizophrenia, bipolar disorder, or depression in some people. Quetiapine has FDA boxed warnings for increased risk of death in adults ...

It works by altering the levels of certain chemical messengers called neurotransmitters in your brain — in particular, serotonin and dopamine. Although it has a sedative effect, quetiapine isn’t ...

Quetiapine oral tablets are prescribed to treat schizophrenia and bipolar disorder, while the extended-release version can also treat major depression when combined with antidepressants. Quetiaine is ...

Augmentation was more effective with quetiapine than lithium for treatment-resistant depression in a pragmatic trial. Quetiapine also improved quality-adjusted life years more than lithium. The ...

May 24, 2007 (San Diego) — A recent study found that among patients in a psychiatric hospital, the atypical antipsychotic quetiapine (Seroquel, AstraZeneca), which is approved for schizophrenia and ...

Please provide your email address to receive an email when new articles are posted on . Nearly 500 members of the International Parkinson and Movement Disorder Society completed the survey. Quetiapine ...

Quetiapine is a drug designed to reduce hallucinations and delusions experienced by people with schizophrenia or bipolar disorder. The most common brand name of quetiapine is Seroquel but it’s also ...

Are you taking Quetiapine? Are you aware of the dangers of combining Quetiapine with certain foods, herbs, or alcohol? Drug-food-interactions are seldom discussed but can lead to undesirable side ...

Learn everything you need to know about Quetiapine-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Quetiapine (Seroquel) was more clinically effective than lithium as a first-line augmentation option in treatment-resistant depression and likely was more cost-effective, a pragmatic multicenter ...